PEPCOL: a GERCOR randomized phase II study of nanoliposomal irinotecan PEP02 (MM‐398) or irinotecan with leucovorin/5‐fluorouracil as second‐line therapy in metastatic colorectal cancer

A multicenter, open‐label, noncomparative, randomized phase II study (PEPCOL) was conducted to evaluate the efficacy and safety of the irinotecan or PEP02 (MM‐398, nanoliposomal irinotecan) with leucovorin (LV)/5‐fluorouracil (5‐FU) combination as second‐line treatment in patients with metastatic co...

Descripción completa

Detalles Bibliográficos
Autores principales: Chibaudel, Benoist, Maindrault‐Gœbel, Frédérique, Bachet, Jean‐Baptiste, Louvet, Christophe, Khalil, Ahmed, Dupuis, Olivier, Hammel, Pascal, Garcia, Marie‐Line, Bennamoun, Mostefa, Brusquant, David, Tournigand, Christophe, André, Thierry, Arbaud, Claire, Larsen, Annette K, Wang, Yi‐Wen, Yeh, C. Grace, Bonnetain, Franck, de Gramont, Aimery
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2016
Materias:
Cancer Biology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4831286/
https://www.ncbi.nlm.nih.gov/pubmed/26806397
http://dx.doi.org/10.1002/cam4.635

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4831286/
https://www.ncbi.nlm.nih.gov/pubmed/26806397
http://dx.doi.org/10.1002/cam4.635

Ejemplares similares